{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:01Z","timestamp":1772166121253,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"consortium for national health research","award":["RCDG-2012-032"],"award-info":[{"award-number":["RCDG-2012-032"]}]},{"name":"Armed Forces Health Surveillance Center \u2013 Department of Defense Global Emerging Infections System","award":["P0209_15_KY"],"award-info":[{"award-number":["P0209_15_KY"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Naturally acquired immunity (NAI), which is characterized by protection against overt clinical disease and high parasitaemia, is acquired with age and transmission intensity. The role of NAI on the efficacy of anti-malarial drugs, including artemisinin-based combinations used as the first-line treatment for uncomplicated\n                      <jats:italic>Plasmodium falciparum,<\/jats:italic>\n                      has not been fully demonstrated. This study investigated the role of NAI in response to artemisinin-based combination therapy (ACT), in symptomatic patients living in western Kenya, a high malaria transmission area.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sera samples from malaria immune participants (n\u2009=\u2009105) in a therapeutic efficacy study were assessed for in vitro growth inhibitory activity against the 3D7 strain of\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      using a fluorescent-based growth inhibition assay (GIA). Participants\u2019 age and parasite clearance parameters were used in the analysis. Pooled sera from malaria na\u00efve participants (n\u2009=\u20096) with no\n                      <jats:italic>Plasmodium<\/jats:italic>\n                      infection from malaria non-endemic regions of Kenya was used as negative control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The key observations of the study were as follows: (1) Sera with intact complement displayed higher GIA activity at lower (1%) serum dilutions (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.0001); (2) there was significant relationship between GIA activity, parasite clearance rate (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.05) and slope half-life (\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.025); and (3) age was a confounding factor when comparing the GIA activity with parasite clearance kinetics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates for the first time there is synergy of complement, pre-existing immunity, and drug treatment in younger patients with symptomatic malaria in a high-transmission area.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-020-03242-4","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T15:03:17Z","timestamp":1588172597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of complement immune response on artemisinin-based combination therapy in a population from malaria endemic region of Western Kenya"],"prefix":"10.1186","volume":"19","author":[{"given":"Christine N. L.","family":"Wanjala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoseah M.","family":"Akala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhards R.","family":"Ogutu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Andagalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-7883","authenticated-orcid":false,"given":"Edwin","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ochiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"3242_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1017\/S0031182015001249","volume":"143","author":"FJ Fowkes","year":"2016","unstructured":"Fowkes FJ, Boeuf P, Beeson JG. Immunity to malaria in an era of declining malaria transmission. Parasitology. 2016;143:139\u201353.","journal-title":"Parasitology"},{"key":"3242_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.pt.2008.08.008","volume":"4","author":"JG Beeson","year":"2008","unstructured":"Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 2008;4:578\u201384.","journal-title":"Trends Parasitol."},{"key":"3242_CR3","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1128\/IAI.01585-07","volume":"76","author":"FH Osier","year":"2008","unstructured":"Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76:2240\u20138.","journal-title":"Infect Immun"},{"key":"3242_CR4","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1073\/pnas.1615875114","volume":"114","author":"R Ataide","year":"2017","unstructured":"Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O\u2019Flaherty K, et al. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci USA. 2017;114:3515\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3242_CR5","volume-title":"World Malaria Report 2017","author":"WHO","year":"2017","unstructured":"WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017."},{"key":"3242_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/infdis\/jix370","volume":"216","author":"CK Mugyenyi","year":"2017","unstructured":"Mugyenyi CK, Elliott SR, Yap XZ, Feng G, Boeuf P, Fegan G, et al. Declining malaria transmission differentially impacts the maintenance of humoral immunity to Plasmodium falciparum in children. J Infect Dis. 2017;216:887\u201398.","journal-title":"J Infect Dis"},{"key":"3242_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.immuni.2015.02.012","volume":"42","author":"MJ Boyle","year":"2015","unstructured":"Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42:580\u201390.","journal-title":"Immunity"},{"key":"3242_CR8","doi-asserted-by":"publisher","first-page":"e3571","DOI":"10.1371\/journal.pone.0003571","volume":"3","author":"FJ McCallum","year":"2008","unstructured":"McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One. 2008;3:e3571.","journal-title":"PLoS One"},{"key":"3242_CR9","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1128\/IAI.00360-09","volume":"77","author":"EE Murhandarwati","year":"2009","unstructured":"Murhandarwati EE, Wang L, Black CG, Nhan DH, Richie TL, Coppel RL. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun. 2009;77:4510\u20137.","journal-title":"Infect Immun"},{"key":"3242_CR10","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1128\/IAI.69.5.3286-3294.2001","volume":"69","author":"AN Hodder","year":"2001","unstructured":"Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun. 2001;69:3286\u201394.","journal-title":"Infect Immun"},{"key":"3242_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1128\/IAI.00960-09","volume":"78","author":"PD Crompton","year":"2010","unstructured":"Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, et al. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun. 2010;78:737\u201345.","journal-title":"Infect Immun"},{"key":"3242_CR12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0972-9062.117475","volume":"50","author":"E Omukunda","year":"2013","unstructured":"Omukunda E, Githeko A, Ndong\u2019a MF, Mushinzimana E, Atieli H, Wamae P. Malaria vector population dynamics in highland and lowland regions of western Kenya. J Vector Borne Dis. 2013;50:85\u201392.","journal-title":"J Vector Borne Dis."},{"key":"3242_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193:673\u20135.","journal-title":"Science"},{"key":"3242_CR14","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1128\/AAC.01607-06","volume":"51","author":"JD Johnson","year":"2007","unstructured":"Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother. 2007;51:1926\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"3242_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1172\/JCI32138","volume":"118","author":"KE Persson","year":"2008","unstructured":"Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, et al. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest. 2008;118:342\u201351.","journal-title":"J Clin Invest."},{"key":"3242_CR16","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1128\/AAC.00527-15","volume":"60","author":"AC Cheruiyot","year":"2016","unstructured":"Cheruiyot AC, Auschwitz JM, Lee PJ, Yeda RA, Okello CO, Leed SE, et al. Assessment of the Worldwide Antimalarial Resistance Network standardized procedure for in vitro malaria drug sensitivity testing using SYBR Green assay for field samples with various initial parasitemia levels. Antimicrob Agents Chemother. 2016;60:2417\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"3242_CR17","unstructured":"Parasite Clearance Estimator. https:\/\/www.wwarn.org\/parasite-clearance-estimator-pce. Accessed 01 Aug 2019."},{"key":"3242_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/1475-2875-10-339","volume":"10","author":"JA Flegg","year":"2011","unstructured":"Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.","journal-title":"Malar J."},{"key":"3242_CR19","doi-asserted-by":"publisher","first-page":"e0162524","DOI":"10.1371\/journal.pone.0162524","volume":"11","author":"LJ Chebon","year":"2016","unstructured":"Chebon LJ, Ngalah BS, Ingasia LA, Juma DW, Muiruri P, Cheruiyot J, et al. Genetically determined response to artemisinin treatment in Western Kenyan Plasmodium falciparum parasites. PLoS ONE. 2016;11:e0162524.","journal-title":"PLoS ONE"},{"key":"3242_CR20","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/infdis\/jiz027","volume":"219","author":"G Odhiambo","year":"2019","unstructured":"Odhiambo G, Bergmann-Leitner E, Maraka M, Wanjala CNL, Duncan E, Waitumbi J, et al. Correlation between malaria-specific antibody profiles and responses to artemisinin combination therapy for treatment of uncomplicated malaria in western Kenya. J Infect Dis. 2019;219:1969\u201379.","journal-title":"J Infect Dis"},{"key":"3242_CR21","doi-asserted-by":"publisher","first-page":"e3557","DOI":"10.1371\/journal.pone.0003557","volume":"3","author":"AE Dent","year":"2008","unstructured":"Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS ONE. 2008;3:e3557.","journal-title":"PLoS ONE"},{"key":"3242_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4269\/ajtmh.2003.69.558","volume":"69","author":"AA Djimde","year":"2003","unstructured":"Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558\u201363.","journal-title":"Am J Trop Med Hyg"},{"key":"3242_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/CMR.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13\u201336.","journal-title":"Clin Microbiol Rev"},{"key":"3242_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-3024.2006.00808.x","volume":"28","author":"K Marsh","year":"2006","unstructured":"Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51\u201360.","journal-title":"Parasite Immunol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03242-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03242-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03242-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T19:11:05Z","timestamp":1722798665000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03242-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03242-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18722\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18722\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18722\/v3","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the scientific and ethics review boards of the Kenya Medical Research Institute, Nairobi Kenya (KEMRI; approved protocol # 2518) and the Institutional Review Board of the Walter Reed Army Institute of Research, Silver Spring, MD (WRAIR; approved protocol #1935). This study was also registered at clinicaltrials.gov (NCT01976780). All participants and\/or their legal guardians gave a voluntary written informed consent before any study procedures commenced.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No personal identifiable data was used in the study. All authors have provided consent to publish the findings in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}